January 8 (SeeNews) - Bulgarian drug maker Sopharma [BUL:SFA] has acquired two headache relief medicines in Poland from independent local sector player Medicofarma, deal advisor Karoll Investment said on Monday.
At the end of 2023, Sopharma purchased over-the-counter (OTC) medicines Coffepirine and Kopiryna, Karoll Investment, part of US advisory group Oaklins, said in a social media post. Karoll, which advised Sopharma, did not provide financial details of the transaction.
You can subscribe to our M&A newsletter here
The two medical products, developed and manufactured by Medicofarma, contain acetylsalicylic acid and caffeine, and have become well established on the Polish market over the past decades.
According to a separate media statement, the transaction will boost the footprint of Sopharma in Poland and support the potential of the two medicines.
Last month, Sopharma said that it booked 14% annual growth in sales revenue between January and November, mostly due to a 21% jump in exports over the same period. The pharmaceutical firm's consolidated sales in Poland rose by roughly a quarter year-on-year in the nine months through September, an earlier interim financial statement shows.
Sopharma has operations in 33 countries, with a portfolio of more than 200 products. Sopharma has three wholly-owned overseas distribution subsidiaries - in Poland, Ukraine and Kazakhstan.